Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (VNRX) is pioneering epigenetic diagnostics through its nucleosomics platform, developing non-invasive blood tests for early cancer detection and NETosis-related conditions. This resource provides investors and healthcare professionals with comprehensive access to verified company developments and clinical milestones.
Our curated news collection delivers timely updates on regulatory progress, partnership announcements, and research breakthroughs. Users will find essential information spanning clinical trial results, licensing agreements, veterinary diagnostic expansions, and financial performance reports.
The page features critical updates including technology validations, international market entries, and peer-reviewed study publications. All content is rigorously verified to ensure accuracy and relevance for strategic decision-making.
Bookmark this page for structured access to VolitionRx's evolving diagnostic solutions across human and animal health sectors. Check regularly for authoritative reporting on innovations transforming routine disease detection through advanced epigenetic analysis.
Volition (NYSE AMERICAN: VNRX) donated its Nu.Q® Vet Cancer Test to HOPE Animal-Assisted Crisis Response Dogs at the organization's annual conference in Virginia Beach on Oct. 17, 2025.
The donation provided screening for crisis-response canines—prioritizing earlier cancer detection for older dogs and high-risk breeds—while Volition and partners handled sample collection and processing. The company also promoted a free DVM360 webinar featuring veterinary oncologist Dr Sue Ettinger on clinical evidence, sample processing, result interpretation, and practice integration.
VolitionRx (NYSE AMERICAN: VNRX) priced an underwritten public offering on Oct 10, 2025 of 11,550,000 common shares with warrants to purchase up to 11,550,000 shares at a public offering price of $0.52 per share-plus-warrant (with $0.01 allocated to the warrant). Each warrant is exercisable immediately at $0.60 and expires five years after issuance. Volition granted the underwriter a 30-day option for an additional 1,732,500 shares with accompanying warrants. Expected aggregate gross proceeds before expenses are approximately $6.0 million, with potential additional proceeds of about $6.9 million if warrants are fully exercised. The offering is expected to close on or about Oct 14, 2025, with net proceeds for R&D, clinical studies, commercialization, working capital and potential acquisitions.
VolitionRx (NYSE AMERICAN: VNRX) announced a proposed underwritten public offering of its common stock and accompanying common stock purchase warrants on October 9, 2025. The company said it will grant the underwriter a 30‑day option to buy up to an additional 15% of the shares and warrants at the public offering price, subject to underwriting discounts and commissions.
Volition intends to use net proceeds for research and product development, clinical studies, commercialization, working capital and potential strategic acquisitions. Newbridge Securities Corporation is sole book‑running manager. The offering is being made from a Form S‑3 shelf registration declared effective on April 18, 2025, and final terms depend on market conditions.
VolitionRx (NYSE AMERICAN: VNRX) announces sponsorship of a GenomeWeb webinar titled "Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery" scheduled for October 8, 2025.
The webinar will feature presentations from Dr. Eric Ariazi, discussing epigenetic pathways and cancer immunoediting, and Dr. Marielle Herzog, R&D director at Belgian Volition, who will present case studies on Nu.Q® assays. The event aims to showcase Volition's Nu.Q® Discover service for drug developers and scientists, focusing on epigenetic profiling in disease model development and clinical studies.
VolitionRx (NYSE AMERICAN: VNRX) has signed a co-marketing agreement with Hologic Diagenode for its Nu.Q® Discover service, which provides epigenetic profiling solutions for drug development and research. The initial one-year agreement could potentially lead to Hologic becoming an exclusive provider of these services.
The Nu.Q® Discover program has an estimated total addressable market of $200 million annually. The partnership leverages Hologic's extensive experience and large client base, having recorded revenues exceeding $4 billion in 2024. The collaboration aims to expand Volition's presence in the pharmaco-epigenetics market by incorporating nucleosome-based biomarkers into Hologic's portfolio for various disease areas including oncology, cardiovascular, and neurodegenerative conditions.
VolitionRx (NYSE AMERICAN: VNRX) has signed its first human out-licensing deal - a Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center for Antiphospholipid Syndrome (APS) applications.
The agreement grants Werfen access to Volition's proprietary Nu.Q® H3.1 NETs assay components to investigate its clinical utility in APS patient management. Werfen has successfully transferred the Nu.Q® NETs assay to their ACL AcuStar® platform, with early results showing promise in detecting NETs levels in APS patients.
APS affects approximately 4 million people worldwide, causing increased blood clot risks and pregnancy complications. The Nu.Q® NETs test represents the first CE-IVD biomarker being investigated for APS, potentially offering improved diagnostic information and ongoing patient monitoring capabilities.
VolitionRx (NYSE AMERICAN: VNRX), a multi-national epigenetics company, reported its Q2 2025 financial results and provided a business update. The company recorded $0.4 million in revenue for Q2, achieving 15% growth in H1 2025 compared to the previous year. Net loss decreased by 11% for Q2 and 24% for H1 year-over-year.
The company is actively pursuing commercialization of its Nu.Q® platform in human diagnostics, engaging in discussions with over ten companies. VolitionRx expects to sign its first human diagnostics agreement this quarter. Cash position stood at $2.3 million as of June 30, 2025, with an additional $1.2 million raised post-quarter through a registered direct offering.
VolitionRx (NYSE AMERICAN: VNRX) has scheduled its Second Quarter 2025 Earnings Conference Call and Business Update for Friday, August 15, 2025, at 8:30 a.m. Eastern Time. The call will be hosted by key executives including Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (President and CEO), Terig Hughes (CFO), and Dr. Andrew Retter (Chief Medical Officer).
The conference call will be accessible via multiple channels, including toll-free numbers for U.S., Canada, and U.K. participants, as well as a live audio webcast. A replay will be available until August 29, 2025. The event will cover Q2 2025 financial results and provide updates on recent developments and upcoming milestones.
VolitionRx (NYSE American: VNRX), a multi-national epigenetics company, has announced a $1.21 million registered direct offering through the sale of common stock and warrants. The offering includes 156,250 shares to company insiders at $0.64 per share, and 1,734,375 shares with accompanying warrants to existing stockholders at the same price.
The warrants allow purchase of up to 1,734,375 additional shares at $0.768 per share, exercisable immediately and expiring in five years. If fully exercised, the warrants could generate an additional $1.3 million. The offering is expected to close around August 5, 2025. Proceeds will support research, product development, clinical studies, and commercialization efforts.
VolitionRx (NYSE AMERICAN: VNRX) reported significant progress in its Nu.Q® Discover program, which has an estimated $200 million annual addressable market. The program now serves over 20 global clients with 14 state-of-the-art immunoassays for epigenetic profiling.
The company's technology was validated in a peer-reviewed publication in the Journal of Biological Chemistry. The largest ongoing project involves a longitudinal Phase 1/2b study expected to complete in 2026, with projected revenue in the hundreds of thousands of dollars.
Volition is exploring co-marketing partnerships and anticipates signing new deals in the coming months, with potential for multi-million dollar partnerships if Nu.Q® assays advance to companion diagnostic use.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
